Our Company

Softhale is a Belgium based pharmaceutical company focused on the development of Soft Mist Inhalation (SMI) devices for the delivery of pharmaceutical drugs to the lungs. Softhale is currently designing and creating a propellant-free, purely mechanical device to be used for worldwide generic and non-generic pharmaceutical development and approval processes, offering innovative as well as cost-optimized device components.

Read more

Our Product

Our next generation SMI devices incorporate a proprietary set of technical configurations to spray a propellant-free liquid formulation in a highly efficient way. Our technology creates an ultra-fine mist using a mechanically-driven impinging working principle, offering a variety of patient benefits:

  • They help the medication pass the natural curve of the throat

  • They give users time to naturally breathe in the medication

  • They help users get the medication deep into their lungs

Read more

Our Journey

In 2012, the founding members of Softhale met and started their conceptual work on a new generation Soft Mist Inhaler (SMI). The team had proven expertise in microfluidic, medical device, pharmaceutical and business development competencies, and the collaboration resulted in a business concept to start a pharmaceutical company. The first patent was filed by the group in 2013.

The team then conducted concept validation work and initial freedom-to-operate analysis, followed by the creation of a business plan. This plan – coupled with the team’s strong background – helped Softhale raise seed funding, leading to early stage proof-of-concept work in 2014-2015.

Since then, the Softhale team has successfully expanded collaborations across geographies, attracting series of funding and investing on a proprietary, innovative approach to inhalation therapy. This led to a successful Series A round, a more than €1 million grant and a first customer-funded proof-of-concept study in 2016.

Softhale NV was established in Diepenbeek, Belgium in 2016 and development activities related to our proprietary next generation SMI intensified.

A Series B round is planned for 2018.


Get to know us

Softhale is a medical device company focused on the development of Soft Mist Inhalation (SMI) devices for the delivery of pharmaceutical drugs to the lungs

Contact Us